Table 4.
Analysis of cutaneous melanoma data using NWDA: identified main effects and interactions.
| Main:G | Age | Gender | Stage | Breslow thickness | Clark level | |
|---|---|---|---|---|---|---|
| Main:E | -0.171 | -0.085 | -0.044 | -0.063 | -0.282 | |
| CCDC90B | -0.111 | |||||
| CEP120 | -0.062 | |||||
| CLN6 | -0.026 | |||||
| CTSA | 0.004 | |||||
| DNAJC6 | 0.007 | |||||
| ELF1 | 0.029 | 0.054 | 0.098 | -0.028 | -0.012 | |
| ELP6 | -0.028 | |||||
| EPHX1 | -0.044 | |||||
| EVPLL | 0.049 | 0.014 | -0.012 | 0.007 | ||
| FAM46A | -0.061 | |||||
| FNDC8 | -0.053 | |||||
| FYTTD1 | -0.075 | |||||
| GAGE2A | -0.047 | |||||
| GNG2 | -0.011 | |||||
| GPATCH11 | -0.033 | |||||
| GSX1 | -0.092 | |||||
| HIPK3 | -0.043 | 0.112 | -0.011 | -0.020 | ||
| HMGCL | -0.053 | |||||
| HMX2 | -0.098 | |||||
| IFITM2 | -0.254 | |||||
| KIAA0319L | 0.095 | |||||
| MMS22L | -0.091 | 0.009 | 0.009 | 0.002 | ||
| MYB | -0.063 | |||||
| NF2 | 0.033 | |||||
| NPHP4 | -0.033 | |||||
| NUDT21 | -0.029 | -0.001 | -0.012 | 0.003 | -0.003 | |
| PHF23 | -0.044 | |||||
| POMGNT1 | 0.094 | 0.008 | ||||
| PRRT4 | -0.120 | |||||
| QSOX2 | 0.085 | |||||
| RAB5A | 0.009 | |||||
| RNF14 | -0.008 | |||||
| SENP6 | -0.075 | |||||
| SOCS3 | 0.014 | -0.001 | 0.002 | -0.008 | 0.004 | 0.002 |
| STMN3 | -0.027 | 0.009 | ||||
| SUCO | -0.080 | |||||
| TP53TG3B | -0.024 | 0.001 | ||||
| TPMT | -0.148 | 0.009 | ||||
| TPM2 | -0.070 | -0.001 | -0.002 | 0.004 | -0.003 | |
| TROVE2 | 0.110 | |||||
| USP46 | -0.007 | |||||
| USPL1 | -0.082 | |||||
| VEPH1 | -0.023 | |||||
| WDR34 | 0.088 |